Photo from wikipedia
The factors important to melanoma patients and clinicians making decisions about adjuvant immunotherapy are not clearly defined. For localized melanoma, surgical resection is standard of care. Recently, adjuvant systemic immunotherapy… Click to show full abstract
The factors important to melanoma patients and clinicians making decisions about adjuvant immunotherapy are not clearly defined. For localized melanoma, surgical resection is standard of care. Recently, adjuvant systemic immunotherapy with anti-PD-1 antibodies has improved survival in resected stage III and IV melanoma, but is costly and incurs toxicity. The goal of our article was to create a comprehensive list of factors important to patients and clinicians when deciding about immunotherapy for all stages of resected melanoma.
Journal Title: Annals of Surgical Oncology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!